JADE CURY MARTINS ASFORA LINS
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
conferenceObject Real-world study of the use of pegylated interferon alfa for treatment of primary cutaneous T-cell lymphomas: an EORTC CLTF study(2022) MITSUNAGA, K.; BAGOT, M.; BEYLOT-BARRY, M.; RAM-WOLFF, C.; GUENOVA, E.; FASSNACHT, C.; HODAK, E.; AMITAY, I.; PAPADAVID, E.; JONAK, C.; PORKERT, S.; SCARISBRICK, J.; APPLEWAITE, R.; NICOLAY, J.; QUAGLINO, P.; SANCHES JR., J.; MARTINS, J. Cury; ORTIZ-ROMERO, P. L.- Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model(2015) SCARISBRICK, Julia J.; PRINCE, H. Miles; VERMEER, Maarten H.; QUAGLINO, Pietro; HORWITZ, Steven; PORCU, Pierluigi; STADLER, Rudolf; WOOD, Gary S.; BEYLOT-BARRY, Marie; PHAM-LEDARD, Anne; FOSS, Francine; GIRARDI, Michael; BAGOT, Martine; MICHEL, Laurence; BATTISTELLA, Maxime; GUITART, Joan; KUZEL, Timothy M.; MARTINEZ-ESCALA, Maria Estela; ESTRACH, Teresa; PAPADAVID, Evangelia; ANTONIOU, Christina; RIGOPOULOS, Dimitis; NIKOLAOU, Vassilki; SUGAYA, Makoto; MIYAGAKI, Tomomitsu; GNIADECKI, Robert; SANCHES, Jose Antonio; CURY-MARTINS, Jade; MIYASHIRO, Denis; SERVITJE, Octavio; MUNIESA, Cristina; BERTI, Emilio; ONIDA, Francesco; CORTI, Laura; HODAK, Emilia; AMITAY-LAISH, Iris; ORTIZ-ROMERO, Pablo L.; RODRIGUEZ-PERALTO, Jose L.; KNOBLER, Robert; PORKERT, Stefanie; BAUER, Wolfgang; PIMPINELLI, Nicola; GRANDI, Vieri; COWAN, Richard; ROOK, Alain; KIM, Ellen; PILERI, Alessandro; PATRIZI, Annalisa; PUJOL, Ramon M.; WONG, Henry; TYLER, Kelly; STRANZENBACH, Rene; QUERFELD, Christiane; FAVA, Paolo; MAULE, Milena; WILLEMZE, Rein; EVISON, Felicity; MORRIS, Stephen; TWIGGER, Robert; TALPUR, Rakhshandra; KIM, Jinah; OGNIBENE, Grant; LI, Shufeng; TAVALLAEE, Mahkam; HOPPE, Richard T.; DUVIC, Madeleine; WHITTAKER, Sean J.; KIM, Youn H.Purpose Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sezary syndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years. Clinical management is stage based; however, there is wide range of outcome within stages. Published prognostic studies in MF/SS have been single-center trials. Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers. Patients and Methods Literature review identified the following 10 candidate markers: stage, age, sex, cutaneous histologic features of folliculotropism, CD30 positivity, proliferation index, large-cell transformation, WBC/lymphocyte count, serum lactate dehydrogenase, and identical T-cell clone in blood and skin. Data were collected at specialist centers on patients diagnosed with advanced-stage MF/SS from 2007. Each parameter recorded at diagnosis was tested against overall survival (OS). Results Staging data on 1,275 patients with advanced MF/SS from 29 international sites were included for survival analysis. The median OS was 63 months, with 2- and 5-year survival rates of 77% and 52%, respectively. The median OS for patients with stage IIB disease was 68 months, but patients diagnosed with stage III disease had slightly improved survival compared with patients with stage IIB, although patients diagnosed with stage IV disease had significantly worse survival (48 months for stage IVA and 33 months for stage IVB). Of the 10 variables tested, four (stage IV, age > 60 years, large-cell transformation, and increased lactate dehydrogenase) were independent prognostic markers for a worse survival. Combining these four factors in a prognostic index model identified the following three risk groups across stages with significantly different 5-year survival rates: low risk (68%), intermediate risk (44%), and high risk (28%). Conclusion To our knowledge, this study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic index, may be useful to stratify advanced-stage patients. (C) 2015 by American Society of Clinical Oncology
- Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey(2023) QUAGLINO, Pietro; SCARISBRICK, Julia; ROCCUZZO, Gabriele; ABELDANO, Alejandra; BATTISTELLA, Maxime; MCCORMACK, Chris; COWAN, Richard; COZZIO, Antonio; CURY-MARTINS, Jade; ENZ, Paula; GESKIN, Larisa; GUENOVA, Emmanuella; KIM, Youn H.; KNOBLER, Robert; LITVINOV, Ivan V.; MIYAGAKI, Tomomitsu; MOLGO, Montserrat; NICOLAY, Jan; PAPADAVID, Evangelina; PINTER-BROWN, Lauren; VALLVERDU, Ramon Pujol; QUERFELD, Christiane; ORTIZ-ROMERO, Pablo; STADLER, Rudolf; VERMEER, Maarten H.; BAGOT, Martine; HODAK, EmmiliaBackground Consensus about the definition and classification of 'plaque' in mycosis fungoides is lacking. ObjectivesTo delineate a comprehensive view on how the 'plaque' entity is defined and managed in clinical practice; to evaluate whether the current positioning of plaques in the TNMB classification is adequate. MethodsA 12-item survey was circulated within a selected panel of 22 experts (pathologists, dermatologists, haematologists and oncologists), members of the EORTC and International Society for Cutaneous Lymphoma. The questionnaire discussed clinical and histopathological definitions of plaques and its relationship with staging and treatment. Results Total consensus and very high agreement rates were reached in 33.3% of questions, as all panellists regularly check for the presence of plaques, agree to evaluate the presence of plaques as a potential separate T class, and concur on the important distinction between plaque and patch for the management of early-stage MF. High agreement was reached in 41.7% of questions, since more than 50% of the responders use Olsen's definition of plaque, recommend the distinction between thin/thick plaques, and agree on performing a biopsy on the most infiltrated/indurated lesion. High divergence rates (25%) were reported regarding the possibility of a clinically based distinction between thin and thick plaques and the role of histopathology to plaque definition. ConclusionsThe definition of 'plaque' is commonly perceived as a clinical entity and its integration with histopathological features is generally reserved to specific cases. To date, no consensus is achieved as for the exact definition of thin and thick plaques and current positioning of plaques within the TNMB system is considered clinically inadequate. Prospective studies evaluating the role of histopathological parameters and other biomarkers, as well as promising diagnostic tools, such as US/RM imaging and high-throughput blood sequencing, are much needed to fully integrate current clinical definitions with more objective parameters.
- Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study(2021) QUAGLINO, P.; PRINCE, H. M.; COWAN, R.; VERMEER, M.; PAPADAVID, E.; BAGOT, M.; SERVITJIE, O.; BERTI, E.; GUENOVA, E.; STADLER, R.; QUERFELD, C.; BUSSCHOTS, A. M.; HODAK, E.; PATSATSI, A.; SANCHES, J.; MAULE, M.; YOO, J.; KEVIN, M.; FAVA, P.; RIBERO, S.; ZOCCHI, L.; RUBATTO, M.; FIERRO, M. T.; WEHKAMP, U.; MARSHALKO, M.; MITTELDORF, C.; AKILOV, O.; ORTIZ-ROMERO, P.; ESTRACH, T.; VAKEVA, L.; ENZ, P. A.; WOBSER, M.; BAYNE, M.; JONAK, C.; RUBETA, M.; FORBES, A.; BATES, A.; BATTISTELLA, M.; AMEL-KASHIPAZ, R.; VYDIANATH, B.; COMBALIA, A.; GEORGIOU, E.; HAUBEN, E.; HONG, E. K.; JOST, M.; KNOBLER, R.; AMITAY-LAISH, I.; MIYASHIRO, D.; CURY-MARTINS, J.; MARTINEZ, X.; MUNIESA, C.; PRAG-NAVEH, H.; STRATIGOS, A.; NIKOLAOU, V.; QUINT, K.; RAM-WOLFF, C.; RIEGER, K.; STRANZENBACH, R.; SZEPESI, A.; ALBERTI-VIOLETTI, S.; FELICITY, E.; CERRONI, L.; KEMPF, W.; WHITTAKER, S.; WILLEMZE, R.; KIM, Y.; SCARISBRICK, J. J.Background The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) in patients with newly diagnosed mycosis fungoides (MF). Objectives To identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB) staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures. Methods In total, 395 newly diagnosed patients with early-stage MF (stage IA-IIA) were recruited from 41 centres in 17 countries between 1 January 2015 and 31 December 2018 following central clinicopathological review. Results The most common first-line therapy was skin-directed therapy (SDT) (322 cases, 81 center dot 5%), while a smaller percentage (44 cases, 11 center dot 1%) received systemic therapy. Expectant observation was used in 7 center dot 3%. In univariate analysis, the use of systemic therapy was significantly associated with higher clinical stage (IA, 6%; IB, 14%; IIA, 20%; IA-IB vs. IIA, P < 0 center dot 001), presence of plaques (T1a/T2a, 5%; T1b/T2b, 17%; P < 0 center dot 001), higher modified Severity Weighted Assessment Tool (> 10, 15%; <= 10, 7%; P = 0 center dot 01) and folliculotropic MF (FMF) (24% vs. 12%, P = 0 center dot 001). Multivariate analysis demonstrated significant associations with the presence of plaques (T1b/T2b vs. T1a/T2a, odds ratio 3 center dot 07) and FMF (odds ratio 2 center dot 83). The overall response rate (ORR) to first-line SDT was 73%, while the ORR to first-line systemic treatments was lower (57%) (P = 0 center dot 027). Health-related QoL improved significantly both in patients with responsive disease and in those with stable disease. Conclusions Disease characteristics such as presence of plaques and FMF influence physician treatment choices, and SDT was superior to systemic therapy even in patients with such disease characteristics. Consequently, future treatment guidelines for early-stage MF need to address these issues.
- Quality of life in patients with mycosis fungoides and Sezary syndrome is significantly worse in female patients, Sezary syndrome and those with more extensive skin involvement(2018) MOLLOY, Kevin; EVISON, Felicity; PENG, Chenjing; GUENOVA, Emmanuella; COWAN, Richard; BUSSCHOTS, Annemie; WOEI-A-JIN, Sherida H.; BERVOETS, An; HAUBEN, Esther; BEYLOT-BARRY, Marie; JONAK, Constanze; KNOBLER, Robert; POKERT, Stefanie; PAPADAVID, Evangelina; VAKEVA, Liisa; MATIN, Rubeta; BATES, Andrew; ESTRACH, Teresa; PRINCE, Miles; TWIGGER, Robert; BERTI, Emilio; VIOLETTI, Silvia Alberti; BAYNE, Mike; MCKAY, Pam; WACHSMUCH, Rachel; AKILOV, Oleg; MCCANN, Susan; DAMASCO, Fabiana; SANCHES, Jose Antonio; MIYASHIRO, Denis; CURY-MARTINS, Jade; TURNER, Deborah; WOBSER, Marion; BENSTEAD, Kim; YOO, Jinah; SCARISBRICK, Julia